CCNB2 (Cyclin B2)

We identified three new major downstream targets of Snail1 that improve our understanding of the role of EMT in limiting stress signaling, apoptosis, and senescence during cell cycle suppression to create a vulnerability for therapeutic targeting.

DEHP may promote the development of BLCA by interacting with key proteins and signaling pathways. This study provides a theoretical basis for understanding the molecular mechanisms of DEHP-induced BLCA and offers references for future prevention and treatment strategies.

In conclusion, NUF2 is upregulated in ACC and is associated with immune cell infiltration. Functional studies demonstrated that NUF2 promotes ACC cell proliferation and migration, suggesting its potential as a therapeutic target for ACC.

MIRTX is a potential therapeutic miRNA in pancreatic cancer cells.

The identified miRNAs exhibit strong regulatory interactions with these hub genes, while serine/threonine protein kinases emerged as the most significantly associated group. Together, these findings highlight promising biomarker candidates and potential therapeutic targets for gynecological cancers.

The results of the receiver operating characteristic (ROC) curve, area under the ROC curve, calibration plot, net reclassification index, integrated discrimination improvement index, and decision curve analysis revealed that the model had good discriminating ability, predictive ability, and clinical utility. In conclusion, AURKA, BUB1, and CDK1 are potential prognostic biomarkers of NPC, and a prediction model incorporating the expression levels of AURKA and BUB1 has good discriminating ability, predictive ability, and clinical utility.

This study systematically reveals that EDCs promote HCC initiation and progression by perturbing cell cycle, metabolic, and immune homeostasis through multi-target, multi-pathway mechanisms. The nine-gene risk model demonstrates superior performance in HCC diagnosis and prognosis and shows potential clinical translational value in drug-sensitivity prediction and pan-cancer analyses. This work provides a new perspective at the intersection of environmental toxicology and precision oncology and informs individualized therapeutic strategies.

The glycolysis-CCNB2-H3K18la-TTK/BUB1B signaling axis exacerbates the malignant progression of PDAC, providing insights into potential lactylation-based therapeutic strategies for this disease.

These findings indicate a strong interaction between lncRNA ADAMTS9-AS1-002 and CCNB2 expression or function, with a substantial contribution to uncontrolled cell proliferation and oncogenic progression in HPV-positive HNSCC. Furthermore, this study also identifies CCNB2 as a critical downstream effector of ADAMTS9-AS1-002, which can be harnessed as a promising molecular signature for therapeutic intervention in head and neck cancers positive for HPV.

9 core genes (CCNB1, CCNB2, MAD2L1, BUB1, TTK, CDC20, AURKA, RRM2, GTSE1) were obtained through the KEGG pathway enrichment, which mainly enriched in 4 pathways, namely, Cell cycle, Oocyte meiosis, p53 signaling pathway, and Progesterone-mediated oocyte maturation, respectively. Nine critical dependable DEGs were identified in limited-stage NSCLC using integrated bioinformatical approaches, and these core genes show great potential as prospective biomarkers and therapeutic targets in the progression of limited-stage NSCLC. non-small cell lung cancer, biomarkers, therapeutic targets, p53 signaling pathway, bioinformatics analysis.

scRNA-seq analysis indicated that HSD17B1 was predominantly expressed in epithelial cells and was significantly involved during their malignant transformation (confirmed by ST). This study identified HSD17B1 as a critical target gene for genistein in GA treatment, emphasizing its roles in the malignant transformation of epithelial cells, thus providing a theoretical foundation for understanding the therapeutic mechanism of genistein in GA.